Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Total Non-Current Liabilities (2021 - 2025)

HCW Biologics (HCWB) has disclosed Total Non-Current Liabilities for 5 consecutive years, with $26.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Non-Current Liabilities changed N/A year-over-year to $26.9 million, compared with a TTM value of $26.9 million through Sep 2025, changed N/A, and an annual FY2024 reading of $37.0 million, up 146.98% over the prior year.
  • Total Non-Current Liabilities was $26.9 million for Q3 2025 at HCW Biologics, down from $27.3 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $37.0 million in Q4 2024 and bottomed at $1.1 million in Q2 2022.
  • Average Total Non-Current Liabilities over 5 years is $15.2 million, with a median of $10.9 million recorded in 2023.
  • Peak annual rise in Total Non-Current Liabilities hit 852.13% in 2023, while the deepest fall reached 34.41% in 2023.
  • Year by year, Total Non-Current Liabilities stood at $2.3 million in 2021, then surged by 303.45% to $9.4 million in 2022, then soared by 59.97% to $15.0 million in 2023, then soared by 146.98% to $37.0 million in 2024, then dropped by 27.42% to $26.9 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for HCWB at $26.9 million in Q3 2025, $27.3 million in Q2 2025, and $34.8 million in Q1 2025.